Publications by authors named "T Traina"
Purpose Of Review: This review aims to describe the association of integrating traditional Chinese medicine (TCM) herbs into conventional medicine (CM) in preventing breast cancer and improving survival rates among breast cancer patients of Taiwan.
Recent Findings: Of 7 relevant studies, spanning 2014-2023, 4 investigated breast cancer risk in women with menopausal symptoms and other comorbidities. All 4 reported that TCM herbal use was associated with lower risks of developing breast cancer.
Oral minoxidil for late alopecia in cancer survivors.
Breast Cancer Res Treat
December 2024
Article Synopsis
- Late alopecia, which is incomplete hair regrowth after chemotherapy or endocrine therapy, affects women's quality of life, leading this study to investigate oral minoxidil as a treatment option.
- The study included 216 patients, primarily women with breast cancer, and found that 74% experienced improvement in hair regrowth after using oral minoxidil for about 3.5 months.
- Results showed significant increases in hair density on both the frontal and occipital areas, indicating that oral minoxidil is well-tolerated and may help cancer survivors with late alopecia.
The KEYNOTE-522 (KN522) regimen for neoadjuvant treatment of triple negative breast cancer (TNBC) utilized q3week dosing for doxorubicin plus cyclophosphamide (AC); however, dose-dense AC (ddAC) has demonstrated superior overall survival (OS) compared to q3week AC in anthracycline and taxane-based regimens. We performed a retrospective analysis assessing the use of ddAC in KN522 and the impact of sequencing ddAC before or after carboplatin/paclitaxel (CbT) plus pembrolizumab on multiple outcomes. 128 patients with TNBC were included.
View Article and Find Full Text PDFArticle Synopsis
- - The use of gonadotropin-releasing hormone (GnRH) agonists has become popular for temporarily suppressing ovarian function in pre-menopausal breast cancer patients undergoing treatment with aromatase inhibitors or tamoxifen, showing positive survival outcomes in studies involving nearly 15,000 women.
- - Previous clinical trials have primarily measured testosterone in prostate cancer and estradiol in breast cancer to evaluate the effectiveness of GnRH agonists.
- - The text emphasizes that estradiol is the preferred biomarker for monitoring ovarian function suppression with GnRH agonist therapy in pre-menopausal breast cancer patients and suggests that future research should focus on maintaining estradiol levels as a key endpoint in trials.
Purpose: We explored the efficacy of PARP inhibition with or without programmed death ligand-1 (PD-L1) blockade as chemotherapy-free maintenance therapy for advanced triple-negative breast cancer (aTNBC) sensitive to platinum-based chemotherapy.
Patients And Methods: In the phase II non-comparative DORA trial (NCT03167619), patients with ongoing stable disease (SD) or complete/partial response (CR/PR) to first- or second-line platinum-based chemotherapy for TNBC (≤10% estrogen/progesterone receptor expression) were randomized 1:1 to receive olaparib 300 mg twice daily with or without durvalumab 1,500 mg on day 1 every 4 weeks. The primary objective was to compare progression-free survival (PFS) versus a historical control of continued platinum-based therapy.